Project Grant R01CA297076
Award Date
1/16/25
Completion Date
12/31/29
Dollars Obligated
$326K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) in the amount of $612,288 provides funding to the University of Wisconsin-Madison to conduct research on the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche for high-grade serous ovarian cancer (HGSOC). The 5-year project, beginning on December 11, 2024 and ending on November 30, 2029, aims to advance the fundamental understanding of the biological...
This federal Project Grant award in the amount of $362,741, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development and evaluation of an ultra-small epigenetic-regulating nanocarrier system for enhanced synthetic lethal cancer therapy. The key objectives are to: 1) optimize a nanocarrier formulation that can effectively deliver the PARP inhibitor BMN673 and the DNA methylation inhibitor 5-azacytidine to tumors; 2) assess the in vivo...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will support the development of a novel spatial proteomics approach to identify immune cell niches within the tumor microenvironment. The $424,734 award, with a project period from December 1, 2024 to November 30, 2026, will be used by the University of Illinois to integrate 3D microscopy techniques with bottom-up proteomic assays. This innovative method aims to provide deep proteome...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $506,309 to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on the regulation of ovarian cancer metastasis. The key objective is to determine how microenvironmental signals activate the transcription factor c-Jun in ovarian cancer cells, while simultaneously exposing new binding sites that increase expression of c-Jun target genes...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...
The National Cancer Institute (NCI) awarded a $483,556 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of New Mexico Health Sciences Center (UNM HSC) to investigate the use of toll-like receptor (TLR) agonist-modified mesoporous silica nanoparticles (MSN) for the treatment of peritoneal metastases in ovarian and colorectal cancers. The project aims to define the mechanisms by which intraperitoneal delivery of the modified-MSN leads to tumor eradication, focusing on...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) totaling $451,996 aims to develop a high-throughput screening platform to identify and validate novel drug therapies targeting migrating and treatment-resistant glioblastoma (GBM) cancer cells. The key products and services to be delivered include: Employing an ex vivo integrated high-throughput platform for quantitative cellular/molecular analysis and biophysical assessment of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $145,000.00 in funding to the University of Oklahoma Health Sciences Center to investigate the role of the JMJD4 enzyme in pancreatic cancer. The research aims to determine how JMJD4 affects the growth and invasiveness of pancreatic tumor cells, as well as its potential mechanisms of action through modulating transcription factors NRF2 and HIF-2A. This work is expected to advance...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $364,848 to Vanderbilt University to develop and test a biomaterial therapy that locally delivers a RIG-I agonist to elicit a pro-inflammatory response in mouse models of glioblastoma (GBM), a deadly form of brain cancer. The project aims to engineer RNA nanoparticles containing a stem-loop 3PRNA agonist for RIG-I activation, which will be delivered via pH-responsive...
This federal Project Grant award, valued at $465,020 and funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research into the mechanisms by which chemotherapy can inadvertently promote metastasis in ovarian cancer. The research project, conducted by the University of Maryland, Baltimore, aims to determine how chemotherapy activates tumor-associated serine proteases (MASPs) that enable the spread and dissemination of ovarian cancer cells....